Media

With strong backgrounds in journalism, our team knows how to position your story for the outlets that matter most to you. We emphasize proactive outreach to reporters; we don’t wait for milestone news to pitch.

This isn’t our target list. It’s our training ground.

More than 50 years combined journalism experience to shape strategies, open doors and get results.

‘Epigenetic Engineering’ Gene Therapy From Epic Bio Shows Early Promise
Featuring Epic Bio
March 16, 2023
Ex-NIH, Sanofi leaders nab Merck support for their biotech’s Epstein-Barr vaccine
Featuring ModeX Therapeutics
March 8, 2023
Volastra licenses Amgen molecule for chromosomally unstable cancers
Featuring Volastra Therapeutics
March 7, 2023
As clinical evidence mounts for bispecific, VCs back Bicara with $108M series B
Featuring Bicara Therapeutics
March 6, 2023
FDA clears Intellia to start US tests of ‘in vivo’ gene editing drug
Featuring Intellia Therapeutics
March 2, 2023
12 conditions from Alzheimer’s to Lyme that Mass. biotechs are developing treatments for now
Featuring Nimbus Therapeutics
February 21, 2023
71-Year-Old Cancer Patient Broke Trial Age Limits for a Chance at a Cure
Featuring Orca Bio
January 8, 2023
Takeda to Pay as Much as $6 Billion for Nimbus Immune-Therapy Drug
Featuring Nimbus Therapeutics
December 13, 2022
TYK2-blocking agent showcases power of atypical kinase
Featuring Nimbus Therapeutics
December 7, 2022
Special report 2022: Meet 20 women blazing trails in biopharma R&D
Featuring Epic Bio
December 7, 2022
CRISPR infusion eliminates swelling in those with rare genetic disease
Featuring Intellia Therapeutics
September 16, 2022
Crispr Gene-Editing Drugs Show Promise in Preliminary Study
Featuring Intellia Therapeutics
September 16, 2022
Freshly baked: Pretzel Therapeutics takes out the oven mitts to drug diseases in the powerhouse of the cell 
Featuring Pretzel Therapeutics
September 12, 2022
Targeting Sugars that Let Cancers Evade the Immune System
Featuring Palleon Pharmaceuticals
August 25, 2022
Wages of CIN could total $1B-plus for Volastra in synthetic-lethality BMS deal
Featuring Volastra Therapeutics
March 21, 2022
Big Pharma is waking up to the booming field of gene editing. Here are the top 18 biotechs to know in 2022 that are poised to grab the drug industry's attention.
Featuring Intellia Therapeutics & Verve Therapeutics
January 31, 2022
A new startup thinks it's found a key to drugging 'disordered' proteins — and it has plenty of cash to get started
Featuring Ambagon Therapeutics
January 7, 2022
Gene Editor Verve Unveils Second Way to Lower Cholesterol
Featuring Verve Therapeutics
November 11, 2021
What's The Outlook From Life Science Operations For 2022 — And Beyond?
Featuring Vor Biopharma, Tenaya Therapeutics, Generation Bio & AVROBIO
Life Science Leader
December 1, 2021
Gene therapy research for frontotemporal dementia: understanding the science and clinical trial considerations
Featuring Prevail Therapeutics
October 19, 2021
Biotech Startup Rome Therapeutics Raises $77 Million in Funding
Featuring Rome Therapeutics
September 14, 2021
Meet the 24 biotech startups that top VCs say are poised to take off in the next 12 months
Featuring Korro Bio and Tenaya Therapeutics
August 2, 2021
Robots, automation and pod factories: How cell and gene therapy makers are catching production up to speed
Featuring AVROBIO
July 26, 2021
Patients to the front: Drug companies and biotechs are creating new roles intended to connect with the patients they aim to help
Featuring Dyne Therapeutics
July 30, 2021
Boston’s Biotechs Pull Out All the Stops in Hiring Boom ‘On Steroids’
Featuring AVROBIO
July 28, 2021
Newer methods may boost gene therapy’s use for more diseases
Featuring AVROBIO
June 2, 2021
CRISPR's Next Frontier: Treating Common Conditions
Featuring Verve Therapeutics
May 5, 2021
This New Covid Vaccine Could Bring Hope to the Unvaccinated World
Featuring CureVac
May 5, 2021
Could unclogging the brain's drainage system improve the efficacy of Biogen's aducanumab in Alzheimer's?
Featuring PureTech Health
April 28, 2021
It’s DNA Day! Here Are 4 Ways Gene Editing Is Transforming Medicine
Featuring Korro Bio
April 25, 2021
AVROBIO is using 'pods' to create gene therapies, and it believes the approach could change the game altogether
Featuring AVROBIO
April 15, 2021
Researchers See a ‘Tractable Approach’ to Taming Cancer Metastasis
Featuring Volastra Therapeutics
April 10, 2021
Exploring Causes of Frontotemporal Dementia—and Potential Treatments
Featuring Prevail Therapeutics
April 6, 2021
Why this early-stage drug-discovery firm chose to grow in New York City
Featuring Volastra Therapeutics
March 25, 2021
CRISPR 2.0: Base Editing in the Groove
Featuring Verve Therapeutics
March 4, 2021
Investors act early as pharmacodynamic data drive Morphic shares
Featuring Morphic Therapeutic
March 1, 2021
Here are some of the best nicknames for workers at local companies
Featuring Dyne Therapeutics and Atalanta Therapeutics
March 1, 2021
A gene therapy pipeline takes shape for a cluster of rare diseases
Featuring AVROBIO
February 12, 2021
Drug startups coalesce around condensates
Featuring Faze Medicines
February 9, 2021
Avrobio gene therapy eliminates toxic substrate in Fabry patient
Featuring AVROBIO
February 8, 2021
Managing cell therapy logistics during COVID-19
Featuring Be The Match BioTherapies
February 2, 2021
Aurinia secures FDA drug approval for autoimmune kidney disease, with label offering stronger patent protection
Featuring Aurinia Pharmaceuticals
January 24, 2021
CureVac partners with Bayer to accelerate vaccine production
Featuring CureVac
January 12, 2021
Myovant scores FDA nod for Orgovyx, a first-in-class pill for advanced prostate cancer
Featuring Myovant Sciences
December 21, 2020
With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million
Featuring Scorpion Therapeutics
January 7, 2021
Roche ups its stake in RNA with $25M Ribometrix deal
Featuring Ribometrix, Inc.
January 6, 2021
Faze Medicines launches with $81M Series A, Alnylam vet heading science in play at biomolecular condensates
Featuring Faze Medicines
December 10, 2020
The next generation of gene therapy for rare diseases forges ahead as developers weather hurdles
Featuring Generation Bio and AVROBIO
December 14, 2020
Pfizer’s celebrated Covid-19 vaccine freezes many people out — but a rival mRNA team says they thawed out a solution
Featuring CureVac
November 12, 2020
Most Admired CEOs: At Myovant, Lynn Seely is eager to 'explore new worlds' (Video)
Featuring Myovant
November 6, 2020
In another win for mRNA, CureVac execs detail the new PhI readout of their vaccine data and why they’re so pumped about it
Featuring CureVac
November 10, 2020
A Startup Is Making Thousands of Gene-Edited Pigs Because Humans Need Their Organs
Featuring Qihan Biotech
October 20, 2020
How Nimbus’ focus on internal pipeline could point to long-awaited exit
Featuring Nimbus Therapeutics
October 19, 2020
Integrin-targeted therapies branch out
Featuring Morphic Therapeutic
October 9, 2020
A reprieve from hemophilia A, but for how long?
Featuring Generation Bio
October 5, 2020
Gene Therapy Startups Extend Biotech’s Legacy
Feauting Generation Bio
October 2, 2020
The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them
Featuring Verve Therapeutics
September 30, 2020
Fierce 15 2020 Winner: CureVac
Featuring CureVac
September 28, 2020
Fierce 15 2020 Winner: Rome Therapeutics
Featuring Rome Therapeutics
September 28, 2020
Jim Broderick reels in a $100M Series B to explore a 'new and big' angle of immune regulation
Featuring Palleon Pharmaceuticals
September 17, 2020
An Audience with Karen Akinsanya
Featuring Schrödinger
September 11, 2020
Casma Therapeutics Banks $50 Million, Plans Muscular Dystrophy Trials
Featuring Casma Therapeutics
September 10, 2020
Animal data in hand, Nessan Bermingham banks $91.5M for Atlas-backed RNA editing play
Featuring Korro Bio
September 10, 2020
Companies Strain to Outdo Each Other with Work-from-Home Perks (Think Ukuleles)
Featuring Nimbus Therapeutics, AVROBIO Inc., Rome Therapeutics, and Schrödinger, Inc.
August 17, 2020
Seres Surges 611% After Colon Therapy Meets Goal in Study
Featuring Seres Therapeutics
August 10, 2020
Daniel O’Day’s I/O dance continues, as Gilead and Tango expand deal up to $6B
Featuring Tango Therapeutics
August 17, 2020
How a biotech CEO figured out Covid-19 surveillance testing for 50 companies with 12-hour turnaround times
Featuring Verve Therapeutics
August 14, 2020
On the heels of a snap $1B raise, CureVac outlines plans to seek emergency OK for Covid-19 vaccine -- shares rocket up
Featuring CureVac
August 14, 2020
Generation Bio Blazes New Trail in Gene Therapy with Non-Viral Approach
Featuring Generation Bio
August 5, 2020
A ‘Cure for Heart Disease’? A Single Shot Succeeds in Monkeys
Featuring Verve Therapeutics
June 27, 2020
Myovant endometriosis drug meets its goal in a second late-stage trial, company says
Featuring Myovant Sciences
June 23, 2020
Big Tech Zeros In on the Virus-Testing Market
Featuring Verve Therapeutics
June 18, 2020
For some biotech employees in the age of COVID-19, the workday starts at the bathroom sink
Featuring Verve Therapeutics, Triplet Therapeutics, and Tango Therapeutics
June 16, 2020
Verve Therapeutics to Take On Heart Disease With $63 Million Funding Round
Featuring Verve Therapeutics
June 11, 2020
A Gene-Editing Shot Could Protect Against Heart Attacks
Featuring Verve Therapeutics
June 30, 2020
As NLRP3 players head for first clinical face-off, Novo, Sanofi fuel trans-Atlantic contender with $55M
Featuring NodThera
June 3, 2020
New research offers hope for a way through the blood-brain barrier, ‘the final frontier for drug delivery’
Featuring AVROBIO and Orchard Therapeutics
June 1, 2020
New drugs make headway against lung, prostate, colon cancers
Featuring Myovant Sciences
May 29, 2020
Avrobio posts 22-month update on Fabry gene therapy trial
Featuring AVROBIO
May 13, 2020
Gamida Cell’s Bone Marrow Transplant Alternative Succeeds In Phase III
Featuring Gamida Cell
May 12, 2020
How big pharma firms are quietly collaborating on new coronavirus antivirals
Featuring Schrödinger
May 1, 2020
GV joins $50 million round in Rome Therapeutics to research ‘junk DNA’ for cancer therapies
Featuring ROME Therapeutics
April 27, 2020
Seeking safe microbiome therapies amid COVID-19 crisis
Featuring Seres Therapeutics
April 17, 2020
Will to Prevail in FTD-GRN Proclaimed, phase I/II gene therapy start near
Featuring Prevail Therapeutics
April 22, 2020
Tango Therapeutics banks $60M to push synthetic lethality drug into the clinic
Featuring Tango Therapeutics
April 9, 2020
The 20 under 40: Inside the next generation of biopharma leaders
Featuring Leslie Meltzer, Orchard Therapeutics and Sadik Kassim, Vor BioPharma
April 6, 2020
Compass Therapeutics' immuno-oncology prospect clears solid tumors in mice
Featuring Compass Therapeutics
April 3, 2020
On Rare Disease Day, Boston area biotechs put a spotlight on patients

“When one of your close friends or family members is touched by a rare disease, the disease is not rare anymore,” said Fred Chereau, CEO of LogicBio Therapeutics Inc.

The Boston Globe
Featuring LogicBio Therapeutics, AVROBIO, Dyne Therapeutics and Orchard Therapeutics
February 28, 2020
Step aside CRISPR, RNA editing is taking off
Featuring Korro Bio
February 4, 2020
Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
Featuring Seres Therapeutics
February 18, 2020
Peer Review: Palleon's first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
Featuring Palleon Pharmaceuticals
February 14, 2020
Brain’s drain
Featuring PureTech Health
February 17, 2020
Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO
Featuring Generation Bio
January 15, 2020
Triplet Therapeutics unveils $59M to try hairpin fix for Huntington’s
Featuring Triplet Therapeutics
December 17, 2019
Aurinia stock soars after breakthrough drug for lupus victims has positive trials
Featuring Aurinia Pharmaceuticals
December 5, 2019
Immune agonist antibodies face critical test
Featuring Compass Therapeutics
December 11, 2019
Here's a $25M seed fund aimed at backing some brash new drug ideas out of the Broad
Featuring Novo Ventures
November 19, 2019
Investors are pouring hundreds of millions into startups trying to cure hearing loss.
Featuring Decibel Therapeutics
October 4, 2019
Alphabet’s GV leads funding in gene editing company Verve
Featuring Verve Therapeutics
May 7, 2019
Meet the exosome, the rising star in drug delivery
Featuring PureTech Health
July 30, 2019
What does Nobel-quality research look like in action?
Featuring Tango Therapeutics
July 30, 2018
Surface CEO plans to break through in immuno-oncology
Featuring Surface Oncology
May 9, 2019
Gates-backed computing platform raises $110 million for new drug push
Featuring Schrödinger
May 19, 2019
First targeted protein degrader hits the clinic
Featuring Cedilla Therapeutics
March 6, 2019
Gene therapy startup Neurogene adds fuel with $68 million round
Featuring Neurogene
February 12, 2019
A capsule tricks your stomach into feeling full; could it treat obesity?
Featuring Gelesis
April 29, 2019
Local researchers celebrate medical breakthrough in post-transplant care
Featuring Talaris Therapeutics
April 19, 2019
A Boston biotech takes on a challenge most companies have avoided: making a better schizophrenia drug
Featuring Karuna Therapeutics
January 10, 2019
They thought hemophilia was a ‘lifelong thing.’ They may be wrong.
Featuring Spark Therapeutics
August 13, 2018
Taking a drug to market is ‘a marathon, not a sprint’
Featuring Molecular Partners
May 16, 2019
What’s next for neoantigens
Featuring Neon Therapeutics
October 10, 2019
‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different.
Featuring Vor Biopharma
August 7, 2019
Biotechs race to develop stem cell treatments for diabetes
Featuring Sigilon Therapeutics
July 15, 2019
One-off injection may drastically reduce heart attack risk
Featuring Verve Therapeutics
May 19, 2019
Morphic bags J&J as second big pharma partner for oral integrins
Featuring Morphic Therapeutic
February 21, 2019
In the red-hot race to fill biotech jobs, benefits abound
Featuring Neon Therapeutics, Cedilla Therapeutics and Tango Therapeutics
October 11, 2018
Gene therapy helped these patients see. Can it transform medicine?
Featuring Spark Therapeutics
October 19, 2017
Can targeting one inflammasome complex solve many diseases? NodThera is betting on it
Featuring NodThera
August 16, 2019
The FDA just approved a new prescription weight-management device. Here’s how it works.
Featuring Gelesis
April 15, 2019